Request Demo
Recent blog posts
Latest Hotspot
8 min read
RP-2(Replimune Group) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
RP-2(Replimune Group): Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Multiple Sclerosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Multiple Sclerosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
InCVAX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
InCVAX: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Neuromyelitis Optica Spectrum Disorder Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Neuromyelitis Optica Spectrum Disorder clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and…
Latest Hotspot
8 min read
Calmangafodipir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Calmangafodipir: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Myasthenia Gravis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Myasthenia Gravis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Bofutrelvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Bofutrelvir: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eosinophilic Esophagitis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Eosinophilic Esophagitis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Tideglusib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Tideglusib: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Celiac Disease Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Celiac Disease clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Crohn Disease Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Crohn Disease clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Fosigotifator Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Fosigotifator: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.